慢性自发性荨麻疹：奥马珠单抗治疗作用机制与疗效评估

doi:10.3760/cma.j.issn.0412-4030.2019.09.014

Abstract

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is characterized by recurrent wheals with severe itching, and greatly affects the life quality of patients. The European guideline on chronic urticaria recommends the anti-IgE monoclonal antibody omalizumab as the only third-line therapy for patients with CSU whose condition can not be controlled by high doses of antihistamines. Although a lot of researches have shown that omalizumab is effective and safe for the treatment of CSU, its therapeutic mechanisms have not yet been fully elucidated. This review summarizes therapeutic mechanisms of omalizumab in the treatment of CSU, and indices for predicting and monitoring its clinical efficacy.

Key words: Urticaria, Immunoglobulin epsilon-chains, Immunoglobulin E, Omalizumab, Chronic spontaneous urticaria

Chen Yudi, Geng Peng, Zhao Jiahui, Tu Ping, Zhao Zuotao. Chronic spontaneous urticaria: therapeutic mechanism of omalizumab and assessment of its clinical efficacy[J].Chinese Journal of Dermatology, 2019, 52(9): 652-655.

References ［23］

［1］	Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750. doi: 10.1016/j.jaci.2015.12.1342.
［2］	Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2015,135（2）:337⁃342. doi: 10.1016/j.jaci.2014.04.036.
［3］	Maurer M, Bindslev⁃Jensen C, Gimenez⁃Arnau A, et al. Chronic idiopathic urticaria （CIU） is no longer idiopathic: time for an update［J］. Br J Dermatol, 2013,168（2）:455⁃456. doi: 10.1111/ j.1365⁃2133.2012.11171.x.
［4］	Dressler C, Rosumeck S, Werner RN, et al. Executive summary of the methods report for ′The EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update′［J］. Allergy, 2018,73（5）:1145⁃1146. doi: 10.1111/all.13414.
［5］	Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria［J］. J Allergy Clin Immunol, 2016,137（2）:474⁃481. doi: 10.1016/j.jaci.2015.08.023.
［6］	Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria［J］. J Allergy Clin Immunol, 2016,137（2）:474⁃481. doi: 10.1016/j.jaci.2015.08.023.
［7］	Asero R, Tedeschi A, Marzano AV, et al. Chronic urticaria: a focus on pathogenesis［J］. F1000Res, 2017,6:1095. doi: 10.12688/ f1000research.11546.1.
［8］	Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis［J］. Immunol Allergy Clin North Am, 2014,34（1）:33⁃52. doi: 10.1016/j.iac.2013.09.012.
［9］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781. doi: 10. 1016/j.jaci.2016.08.050.
［10］	Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects［J］. Allergy, 2014,69（6）:683⁃691. doi: 10.1111/all.12389.
［11］	Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system［J］. Allergol Int, 2018,67（2）:191⁃194. doi: 10.1016/j.alit.2017.09.003.
［12］	Kaplan AP, Giménez⁃Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria［J］. Allergy, 2017,72（4）:519⁃533. doi:10.1111/all.13083.
［13］	Serrano⁃Candelas E, Martinez⁃Aranguren R, Valero A, et al.Comparable actions of omalizumab on mast cells and basophils［J］. Clin Exp Allergy, 2016,46（1）:92⁃102. doi:10.1111/cea. 12668.
［14］	Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic （IgE⁃mediated） asthma; PKPD analysis of a biomarker, total IgE［J］. Br J Clin Pharmacol, 2011,72（2）:306⁃320. doi: 10.1111/j.1365⁃2125.2011.03962.x.
［15］	Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin［J］. Theranostics, 2017,7（5）:1266⁃1276. doi: 10.7150/thno.18304.
［16］	Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell Fc epsilon RI expression and function［J］. J Allergy Clin Immunol, 2004,114（3）:527⁃530. doi: 10.1016/j.jaci.2004.06.032.
［17］	Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell Fc epsilon RI expression and function［J］. J Allergy Clin Immunol, 2004,114（3）:527⁃530.
［18］	Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,140（6）:1749⁃1751. doi: 10.1016/j.jaci.2017.08. 007.
［19］	Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,139（3）:1059⁃1061. doi: 10.1016/j.jaci.2016.07.047.
［20］	Deza G, Bertolín⁃Colilla M, Pujol RM, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of pesponse to omalizumab therapy［J］. Acta DermVenereol, 2017,97（6）:698⁃704. doi: 10.2340/000155 55⁃2654.
［21］	Palacios T, Stillman L, Borish L, et al. Lack of basophil CD203c⁃upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria［J］. J Allergy Clin Immunol Pract, 2016,4（3）:529⁃530. doi: 10.1016/j.jaip.2015.11.025.
［22］	Asero R. D⁃dimer: a biomarker for antihistamine⁃resistant chronic urticaria［J］. J Allergy Clin Immunol, 2013,132（4）:983⁃986. doi: 10.1016/j.jaci.2013.04.037.
［23］	Asero R, Marzano AV, Ferrucci S, et al. D⁃dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria［J］. Int Arch Allergy Immunol, 2017,172（1）:40⁃44. doi: 10.1159/000453453.

[1]	Zhang Yu, Han Yue, Xu Beilei, Ling Shiqi, Luo Yang, Liu Xiaochun, Yao Xu. Establishment of a mouse model of atopic dermatitis induced by topical application of ovalbumin and calcipotriol [J]. Chinese Journal of Dermatology, 2019, 52(7): 481-485.
[2]	Xu Yanfeng, Du Weiping, Luo Zhicheng, Shen Hailian. Efficacy of desloratadine citrate disodium in the treatment of chronic urticaria and its effect on serum interleukin-23, interleukin-33 and PARC/CCL-18 [J]. Chinese Journal of Dermatology, 2019, 52(5): 337-339.
[3]	Luo Jincheng, Chen Shuguang, Liu Wenying, Xu Yan, Song Zhiqiang. Effect of autologous whole blood injections on expression of FcεRⅠ and CD63 on basophils in patients with refractory chronic spontaneous urticaria and positive autologous serum skin test [J]. Chinese Journal of Dermatology, 2019, 52(4): 241-247.
[4]	Chen Anwei, Bai Xiaoming, Wang Hua. Mas-related G protein-coupled receptor X2: a novel receptor for non-IgE-dependent activation of mast cells [J]. Chinese Journal of Dermatology, 2019, 52(2): 142-144.
[5]	WANG Gang. Main adverse reactions in biological agents in dermatology and their strategies [J]. Chinese Journal of Dermatology, 2019, 52(2): 77-80.
[6]	Centre for Urticaria Research, Chinese Society of Dermatology. Guideline for diagnosis and treatment of urticaria in China （2018） [J]. Chinese Journal of Dermatology, 2019, 52(1): 1-5.
[7]	Zheng Lin, Shi Zhenrui, He Mintong, Tan Guozhen. Omalizumab for the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2019, 52(1): 60-63.
[8]	Duan-Chong. Association of serum gastrin?releasing peptide levels with disease activity and pruritus in patients with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2018, 51(7): 533-535.
[9]	. Excessive selenium supplementation aggravates atopic dermatitis-like skin lesions induced by dinitrochlorobenzene in mice [J]. Chinese Journal of Dermatology, 2018, 51(7): 495-499.
[10]	. Efficacy and safety of omalizumab on the treatment of chronic spontaneous urticaria: a meta-analysis [J]. Chinese Journal of Dermatology, 2018, 51(6): 472-475.
[11]	. Retrospective analysis of 185 inpatients with acute urticaria [J]. Chinese Journal of Dermatology, 2018, 51(3): 224-227.
[12]	Lu Rongbiao, Su Xiangyang, Yao Tingting, Li Meirong, Li Huizhu, Ye Cuifen, Lai Wei. Analysis of provocative test results in 127 cases of suspected inducible urticaria [J]. Chinese Journal of Dermatology, 2018, 51(11): 806-808.
[13]	Dong YIN. A case of urticaria?like follicular mucinosis [J]. Chinese Journal of Dermatology, 2017, 50(6): 454-455.
[14]	Li Yuanjun, Zhang Xinglian, Zhang Huanzhen, Zhang Xianhui, Liu Runtao, Wang Hui, Han Yuyang, Li Junna, Liu Qiang. Association analysis between the serum level of vitamin D and severity of atopic dermatitis in infants [J]. Chinese Journal of Dermatology, 2017, 50(11): 825-828.
[15]	Yi-Kui Hou. Efficacy of rupatadine versus mizolastine in the treatment of chronic urticaria: a clinical observation [J]. Chinese Journal of Dermatology, 2017, 50(10): 754-755.

Chronic spontaneous urticaria: therapeutic mechanism of omalizumab and assessment of its clinical efficacy

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References ［23］

Related Articles 15

Metrics

Comments

Recommended 10